2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-139024
    ACAT-IN-7 199984-38-8 98%
    ACAT-IN-7 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-7 inhibits NF-κB mediated transcription.
    ACAT-IN-7
  • HY-139025
    ACAT-IN-8 199984-35-5 98%
    ACAT-IN-8 (example 206) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-8 inhibits NF-κB mediated transcription.
    ACAT-IN-8
  • HY-139026
    ACAT-IN-9 199984-40-2 98%
    ACAT-IN-9 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 207. ACAT-IN-9 inhibits NF-κB mediated transcription.
    ACAT-IN-9
  • HY-139027
    ACAT-IN-10 454203-40-8 98%
    ACAT-IN-10 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 197. ACAT-IN-10 weakly inhibits NF-κB mediated transcription.
    ACAT-IN-10
  • HY-139043
    6-B345TTQ 297157-87-0 98%
    6-B345TTQ is an α4 integrin inhibitor that inhibits α4-Leupaxin interaction. 6-B345TTQ can be used in inflammation research.
    6-B345TTQ
  • HY-139112
    Leukotriene B4 dimethyl amide 83024-92-4 98%
    Leukotriene B4 dimethyl amide, an immunomodulator, stimulates contraction of isolated guinea pig lung entities. Leukotriene B4 (LTB(4)) also stimulates human neutrophil migration, and LTB(4) antagonists may have anti-inflammatory activity in inflammatory pathophysiology.
    Leukotriene B4 dimethyl amide
  • HY-139125
    DCHC 302953-06-6 98%
    DCHC is a SIRT1 activator but does not induce SIRT1 expression. DCHC can be used for mitochondrial damage related studies.
    DCHC
  • HY-139174
    (S)-DO271 2301865-01-8 98%
    (S)-DO271 is a non-active control probe targeting ABHD12, and it has almost no inhibitory activity against ABHD12 (IC50 > 100 μM). (S)-DO271 does not cause the upregulation of inflammatory factors and has no cytotoxicity. (S)-DO271 is suitable as a negative control for validating the functional studies of ABHD12.
    (S)-DO271
  • HY-139184
    CCR5 antagonist 4 872879-86-2 98%
    CCR5 antagonist 4 is an orally active CCR5 antagonist. CCR5 antagonist 4 can be studied in research on rheumatoid arthritis.
    CCR5 antagonist 4
  • HY-139247
    pNPS-DHA 2454246-25-2 98%
    pNPS-DHA (Compound 19) is an orally active DHA-ethanolamide (DHEA) derivative that has antiallergic activity. pNPS-DHA inhibits IgE-dependent passive cutaneous anaphylaxis (PCA) reaction in mice. pNPS-DHA has anti-degranulating activity in RBL-2H3 mast cells with an IC50 of 15 μM.
    pNPS-DHA
  • HY-139430
    4-Isopropylcatechol 2138-43-4 98.03%
    4-Isopropylcatechol is a potent and irreversible cutaneous depigmenting agent. 4-Isopropylcatechol significantly inhibits protein biosynthesis in mouse melanoma cells containing high levels of tyrosinase. 4-Isopropylcatechol can be use to study hyperpigmentation of skins.
    4-Isopropylcatechol
  • HY-139555
    Zectivimod 1623066-63-6 99.35%
    Zectivimod is a sphingosine-1-phosphate receptor agonist. Zectivimod can be used for the research of autoimmune diseases，chronic inflammatory diseases and immunoregulation disorders.
    Zectivimod
  • HY-13956A
    (R)-Pioglitazone-d1 1259828-75-5 98%
    (R)-Pioglitazone-d1 ((R)-U 72107-d1) is a stabilized and deuterated R-enantiomer of pioglitazone, exhibiting pharmacological properties that are beneficial for NASH treatment, including modulation of mitochondrial function, non-steroidal anti-inflammatory effects, and glucose-lowering capabilities.
    (R)-Pioglitazone-d1
  • HY-139594
    Polyketide synthase 13-IN-1 2345638-96-0 98%
    Polyketide synthase 13-IN-1 (compound 32) is a polyketide synthase 13 inhibitor.
    Polyketide synthase 13-IN-1
  • HY-139595
    Polyketide synthase 13-IN-2 2219338-48-2 98%
    Polyketide synthase 13-IN-2 (comp 42) is a polyketide synthase 13 inhibitor against Mycobacterium tuberculosis, with an MIC of 0.25 μg/mL.
    Polyketide synthase 13-IN-2
  • HY-139596
    Polyketide synthase 13-IN-3 2221801-50-7 98%
    Polyketide synthase 13-IN-3 (compound 41) is a polyketide synthase 13 inhibitor，with a MIC of 0.0625-0.125 μg/mL against the M. tuberculosis strain H37Rv.
    Polyketide synthase 13-IN-3
  • HY-139627
    P2X receptor-1 3051864-35-5 98%
    P2X receptor-1 is a potential inhibitor of P2X receptor for the research of pain and inflammation.
    P2X receptor-1
  • HY-139709
    Glucocorticoids receptor agonist 1 694526-54-0 98%
    Glucocorticoids receptor agonist 1 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.
    Glucocorticoids receptor agonist 1
  • HY-139710
    Glucocorticoids receptor agonist 2 614761-20-5 98%
    Glucocorticoids receptor agonist 2 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.
    Glucocorticoids receptor agonist 2
  • HY-139716
    IMD-catechol 2928463-39-0 98%
    IMD-catechol is a novel imidazoquinolinone-NF-κB immunomodulator dimer that improves efficacy in a CT26 mouse colon carcinoma tumor model while eliciting minimal adjuvant toxicity.
    IMD-catechol
Cat. No. Product Name / Synonyms Application Reactivity